Lanadelumab
Angioedema
monoclonal_antibodyDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Angioedema cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Firazyr Shire | Phase 3 | BB |
Deucrictibant Institute for Asthma and Allergy | Phase 1/2 | CCC |
HEPARIN University of Iowa | N/A | D |
Recombinant Human C1 Inhibitor Pharming Technologies B.V. | Phase 3 | NR |
Same molecule, other indications
Lanadelumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →